Valneva Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lyon France (2013)

Organization Overview

First Clinical Trial
2013
NCT00602784
First Marketed Drug
2013
inactivated japanese encephalitis vaccine (Ixiaro)
First NDA Approval
2023
Chikungunya Vaccine, Live (IXCHIQ)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Valneva Austria GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Borrelia Infections (Phase 2)

Chikungunya Fever (Phase 3)

Clostridium Infections (Phase 2)

Diarrhea (Phase 2)

Encephalitis (Phase 4)

Encephalitis, Japanese (Phase 4)

Escherichia coli Infections (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Lyme Neuroborreliosis (Phase 1)

Pneumococcal Infections (Phase 1)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Pseudomonas Infections (Phase 3)

Virus Diseases (Phase 3)

Zika Virus Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial APIs: 20